04:42 PM EST, 01/28/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) reported a fiscal Q4 net loss Tuesday of $0.75 per diluted share, narrowing from the loss of $0.77 a year earlier.

Analysts polled by FactSet expected a loss of $0.69.

Revenue in the three months ended Nov. 30 fell to $13.3 million from $15.2 million a year earlier.

Analysts surveyed by FactSet expected $14.6 million.